LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:
| Piper Sandler 37th Annual Healthcare Conference | |
| Format: | Fireside Chat & 1x1 Meetings |
| Date: | Tuesday, December 2, 2025 |
| Time: | 11:30 AM EST |
| Evercore ISI 8th Annual Healthcare Conference | |
| Format: | Fireside Chat & 1x1 Meetings |
| Date: | Wednesday, December 3, 2025 |
| Time: | 3:50 PM EST |
Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.
Investors are invited to review the company corporate deck found on the Events & Presentations page, as well as the replay from the recent virtual KOL Event to discuss EQ504: A Novel Aryl Hydrocarbon Receptor (AhR) Modulator for Ulcerative Colitis.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways.
For more information, visit www.equilliumbio.com.
Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.86 |
| Daily Change: | -0.04 -4.70 |
| Daily Volume: | 235,350 |
| Market Cap: | US$52.370M |
November 13, 2025 October 22, 2025 October 06, 2025 August 11, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
